Finally, long-term relief.
An exciting innovation in urethral stricture treatment—the Optilume drug coated balloon was inspired by severe patient and physician dissatisfaction with current stricture solutions.
This proprietary technology combines balloon dilation and drug delivery. Rapid uptake of the highly lipophilic drug, paclitaxel, limits hyperactive cell proliferation and the fibrotic scar tissue generation that results in stricture recurrence.
How it works.
The safe, well-tolerated procedure is similar to traditional mechanical dilation methods and has a minimal learning curve. Localized drug delivery through micro tissue separations created by balloon expansion ensures that circumferential drug effectively covers the stricture.
Balloon inflates to create micro-fissures in the tissue, providing a pathway for full drug absorbtion.
Hydrophillic coating facilitates rapid release of paclitaxel.
Hydrophobic and lipophilic properties support rapid celluar uptake—enabling the drug to pass through the urethral wall and take up residency in the tissue.
By combining a simple, effective balloon dilation with localized delivery of a proven anti-proliferative —Optilume ends the high recurrence cycle of failed endoscopic stricture management.
The semi-compliant inflatable balloon expands to create micro-fissures in the tissue, facilitating full drug absorption
A hydrophilic coating dissolves in saline (urine) for rapid drug release. The hydrophobic and lipophilic properties of the drug enable it to pass through the urethral wall and achieve residency in the tissue
Travels easily over the guidewire and can cross tight strictures without causing trauma
- Ends the high recurrence cycle of failed endoscopic stricture management
- Minimally invasive
- Compatible with flexible cystoscopes for maximum patient comfort
- Balloon dynamic compliance provides optimal expansion for urology applications
"The Optilume Drug Coated Balloon provides us the opportunity to maintain the low impact nature of balloon dilation while achieving success rates that may approach those of open surgery."
Cloverfields Professor and Vice Chair of Urology
University of Minnesota, Principle Investigator for the Urotronic ROBUST 1 clinical study